Annual TPD and Induced Proximity Summit on October 26-28, 2026 in Boston, United States

After a decade of innovation, the TPD field has its first drug approval in the form of Arvinas' Veppanu. Combined with the recovering market of 2026, this clinical validation will unleash a new wave of innovative approaches and push TPD to a new inflection point. Already, the headwinds are reversing with $15B worth of upfront deals involving TPD candidates and companies in 2026 alone.

However, following the risk-averse funding environment of 2025, continued positive clinical data is key to regaining investor confidence and pharma interest. That's why the 9th TPD and Induced Proximity Summit is returning as the globe's definitive forum to help you gain that ever-important clinical validation. As the world's largest and most comprehensive TPD conference featuring the latest data from early discovery to clinical development, it is designed to help you discover the best novel targets, optimize your degrader profile, and accelerate your pipelines to the clinic and beyond.

URLs:

Website: https://go.evvnt.com/3658229-0?pid=10008

Tickets: https://go.evvnt.com/3658229-2?pid=10008

Brochure: https://go.evvnt.com/3658229-3?pid=10008

Prices:

Drug Developer - Conference + Academic Frontiers Day AND Future Technologies and Innovation Day: USD 5895.00,

Drug Developer - Conference + Academic Frontiers Day OR Future Technologies and Innovation Day: USD 4497.00,

Drug Developer - Conference Only: USD 3099.00,

Academic Pricing - Conference + Academic Frontiers Day AND Future Technologies and Innovation Day: USD 5095.00,

Academic Pricing - Conference + Academic Frontiers Day OR Future Technologies and Innovation Day: USD 3897.00,

Academic Pricing - Conference Only: USD 2699.00,

Service Provider Pricing - Conference + Academic Frontiers Day AND Future Technologies and Innovation Day: USD 7295.00,

Service Provider Pricing - Conference + Academic Frontiers Day OR Future Technologies and Innovation Day: USD 5597.00,

Service Provider Pricing - Conference Only: USD 3899.00

Speakers: Anita Bellail, Chief Executive Officer, HB Therapeutics, Inc, Kara Carter, Chief Executive Officer, Viraccio Therapeutics, Justin Wolfe, Co-Founder and Chief Scientific Officer, Transcera Inc, Adam Yaari, Chief Executive Officer, Serinus Biosciences, Giovanni Spagnolli, Co-Founder and Chief Technology Officer, Sibylla Biotech srl, Benedict CS Cross, Founder and Chief Executive Officer, Stick Therapeutics, Nicki Thompson, Chief Executive Officer, Trimtech Therapeutics, Lan Huang, Co-Founder, Chairman and Chief Executive Officer, Seed Therapeutics, Matthias Brand, Chief Technology Officer, Proxygen GmbH, Eddine Saiah, Chief Executive Officer, Stablix, Jase Brouwer, Chief Scientific Officer, Proxima Bio, Hyunsun Jo, Founder and Chief Executive Officer, Pin Therapeutics, Eran Seger, Chief Executive Officer and Co-Founder, Protai, Catherine Sabatos-Peyton, Chief Executive Officer, Larkspur Biosciences, Leo Fu, Co-Founder and Chief Technological Officer, GluBio, Daohong Zhou, Board Member and Scientific Co-Founder, Dialectic Therapeutics, Yaron Sfadyah, Chief Executive Officer, Coltac Therapeutics, Stacy Blain, Chief Executive Officer, Concarlo Holdings LLC, Ian Churcher, CEO and Founder, Janus Drug Discovery Consulting Ltd, Phil Chamberlain, Chief Executive Officer, Neomorph, Beth Hoffman, Chief Executive Officer, Origami Therapeutics, Inc., Chad May, Chief Scientific Officer, Orum Therapeutics, Marina Nelen, Vice President and Head of Drug Discovery, Foghorn Therapeutics, Elham Behshad, Senior Director, SK Life Science Labs, Kevin Freeman-Cook, Senior Vice President and Head of Chemistry, Plexium Inc., Nathan Shapiro, Vice President, Head of Medicinal Chemistry, Pallando Therapeutics, Andrew Buesking, Senior Director, Chemistry, Prelude Therapeutics, Venkatesan Raghavan, Ph.D., Executive Director, Search and Evaluation Oncology, Novartis AG, Zach Hill, Vice President, Discovery Chemistry, Montara Therapeutics, Debora Bonenfant, Vice President and Head of Proteomics, Monte Rosa Therapeutics, Carla Bauer, Director, Oncology Search and Evaluation, Business Development and Licensing, Merck and Co, Elena Diez Cecilia, Senior Director External Innovation, Johnson and Johnson, Karanbir Pahil, Senior Principal Scientist, GlaxoSmithKline, Evisa Gjini-Bood, Executive Director, Head of Translational Medicine, Flare Therapeutics, Adam Gilbert, Science Partner, Flagship Pioneering, Jonathan Gilbert, Senior Director, Ecosystem Growth and Contributor Partnerships, Eli Lilly and Co., Aparajita Chourasia, Senior Vice President, Drug Development and Biology, BioTheryx, Laura Silvian, Senior Director, Biogen, Takashi Sugane, Head, Candidate Delivery, Engineered Small Molecules, Astellas Pharma, Itsuro Nagase, Senior Vice President, Head of Primary Focus Lead - Targeted Protein Degradation, Astellas Pharma, Alyn Davies, Associate Director, Medicinal Chemistry, AstraZeneca, Ryan Potts, Vice President and Head of Induced Proximity Platform, Amgen Inc., Meizhong Jin, Senior Director, Oncology Chemistry, AstraZeneca, Zoran Rankovic, Professor of Chemical Biology and Director of the Centre for Protein Degradation, Institute of Cancer Research, Gisele Nishiguchi, Targeted Protein Degradation Center Leader, St. Jude Children's Research Hospital, Chunhai Hao, Bicentennial Chair and Professor, Indiana University School of Medicine

Category: Conferences

Date and Time: 26th October 2026 at 8:00 am to 28th October 2026 at 5:00 pm